{"id":"W2619858681","doi":"10.1016/s1470-2045(17)30376-5","title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":539,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Breast cancer; Placebo; Internal medicine; Metastatic breast cancer; Oncology; Cancer; Aromatase inhibitor; Estrogen receptor; Tamoxifen; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001915416,0.0007759189,0.001967269,0.0001258343,0.0009087071,0.0001485439,0.001710759,0.0007115697,0.0002047033],"category_scores_gemma":[0.0003785466,0.0006033732,0.0003486598,0.0001666808,0.0009476177,0.00005481239,0.0004460631,0.00091766,0.0000378416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007610809,"about_ca_system_score_gemma":0.001801409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001259578,"about_ca_topic_score_gemma":0.002348752,"domain_scores_codex":[0.9950958,0.0008918995,0.001034458,0.001188946,0.0004643722,0.001324554],"domain_scores_gemma":[0.9960811,0.0006665515,0.001092314,0.001601036,0.0002656818,0.0002933829],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8667482,0.0004368385,0.0000161172,0.00002683688,0.0007395917,0.00008483009,0.0004677753,0.001767734,0.1244109,0.00007801742,0.002118069,0.003105109],"study_design_scores_gemma":[0.9630767,0.006175831,0.000117464,0.00009541545,0.000325697,0.00007787204,0.0002576781,0.0003251168,0.01773708,0.00005418069,0.01100058,0.0007563927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.976962,0.002694461,0.0001657691,0.004741106,0.003021,0.006623859,0.0006408256,0.00006307281,0.005087887],"genre_scores_gemma":[0.987353,0.003535581,0.0005135144,0.0005260637,0.00361935,0.003443747,0.0001881271,0.0001133838,0.000707188],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1066738,"threshold_uncertainty_score":0.9996418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04915608166519876,"score_gpt":0.3711958041582476,"score_spread":0.3220397224930489,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}